Testosterone therapy helped elderly males with low testosterone levels and pre-existing coronary artery disease reduce their risks of major adverse cardiovascular (CV) events, including strokes, heart attacks, and death. Full findings of the study were presented at the American College of Cardiology’s 65th Annual Scientific Session.
Brent Muhlestein, MD, from the Intermountain Medical Center Heart Institute, and colleagues conducted a study in 755 male patients aged between 58–78 years all with severe coronary artery disease. The patients were divided into 3 different groups that received different doses of testosterone given as an injection or gel.
Data showed after one year, 64 patients not taking testosterone supplements suffered major adverse CV events compared to only 12 patients taking medium doses and 9 patients taking high doses. After 3 years, 125 patients not taking testosterone supplements suffered major adverse CV events compared to only 38 patients taking medium doses and 22 patients taking high doses.
These findings confirm the data of a 2015 study that found testosterone supplementation did not increase the risk of experiencing a heart attack or stroke for men with low testosterone levels and no prior history of heart disease. Also in 2015, the Food and Drug Administration (FDA) mandated all manufacturers of approved testosterone products to add labels outlining the coronary risks of testosterone supplementation.
Dr. Muhlestein added that the new data does not provide enough evidence to justify changes to treatment recommendations. “It does, however, substantiate the need for a randomized clinical trial that can confirm or refute the results of this study.”
For more information visit ihc.com.